Literature DB >> 12238576

Risk factors for recurrence of Clostridium difficile-associated diarrhea in the elderly.

Sari Tal1, Alexander Gurevich, Vladimir Guller, Irina Gurevich, David Berger, Shmuel Levi.   

Abstract

Risk factors that influence the recurrence of nosocomial Clostridium difficile-associated diarrhea (CDAD) were determined in an 18-month follow-up study in a subacute geriatric department. A case-control study was conducted, comparing 43 patients with recurrent C. difficile-associated diarrhea (RCDAD) (case patients) with 38 patients who had only 1 episode of CDAD (control patients). The mean age of patients was 81.6 +/- 7.2 y (range 64-95 y). All cases with CDAD were receiving antibiotic therapy. RCDAD occurred in 53.1% of patients. Risk factors for RCDAD included fecal incontinence (p < or = 0.04), longer duration of fever from admission until first episode of CDAD (p < or = 0.02) and H2-antagonist treatment (p < or = 0.02). This study shows that RCDAD is a common clinical event in elderly hospitalized patients and may be predictable in some groups of patients.

Entities:  

Mesh:

Year:  2002        PMID: 12238576     DOI: 10.1080/00365540210147525

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  11 in total

Review 1.  Recurrent Clostridium difficile infection and the microbiome.

Authors:  Rowena Almeida; Teklu Gerbaba; Elaine O Petrof
Journal:  J Gastroenterol       Date:  2015-07-08       Impact factor: 7.527

2.  Can metronidazole still be used for treatment of Clostridium difficile infections?

Authors:  Haihui Huang; Carl Erik Nord
Journal:  Curr Infect Dis Rep       Date:  2009-01       Impact factor: 3.725

Review 3.  Probiotics for antibiotic-associated diarrhea: do we have a verdict?

Authors:  Iyad Issa; Rami Moucari
Journal:  World J Gastroenterol       Date:  2014-12-21       Impact factor: 5.742

Review 4.  Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis.

Authors:  Raseen Tariq; Siddharth Singh; Arjun Gupta; Darrell S Pardi; Sahil Khanna
Journal:  JAMA Intern Med       Date:  2017-06-01       Impact factor: 21.873

Review 5.  The changing epidemiology of Clostridium difficile infections.

Authors:  J Freeman; M P Bauer; S D Baines; J Corver; W N Fawley; B Goorhuis; E J Kuijper; M H Wilcox
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

6.  Clinical predictors of recurrent Clostridium difficile infection in out-patients.

Authors:  R Shivashankar; S Khanna; P P Kammer; W Scott Harmsen; A R Zinsmeister; L M Baddour; D S Pardi
Journal:  Aliment Pharmacol Ther       Date:  2014-07-10       Impact factor: 8.171

7.  Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients.

Authors:  Daniel E Freedberg; Hojjat Salmasian; Carol Friedman; Julian A Abrams
Journal:  Am J Gastroenterol       Date:  2013-09-24       Impact factor: 10.864

8.  Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters.

Authors:  Efi Kokkotou; Alan C Moss; Athanasios Michos; Daniel Espinoza; Jeffrey W Cloud; Nasima Mustafa; Michael O'Brien; Charalabos Pothoulakis; Ciarán P Kelly
Journal:  Antimicrob Agents Chemother       Date:  2008-01-14       Impact factor: 5.191

9.  Risk factors for recurrence of Clostridium difficile infection: effect of vancomycin-resistant enterococci colonization.

Authors:  Hee Kyoung Choi; Kye Hyung Kim; Sun Hee Lee; Su Jin Lee
Journal:  J Korean Med Sci       Date:  2011-06-20       Impact factor: 2.153

Review 10.  Reducing and managing faecal incontinence in people with advanced dementia who are resident in care homes: protocol for a realist synthesis.

Authors:  Claire Goodman; Jo Rycroft Malone; Christine Norton; Danielle Harari; Rowan Harwood; Brenda Roe; Bridget Russell; Mandy Fader; Marina Buswell; Vari M Drennan; Frances Bunn
Journal:  BMJ Open       Date:  2015-07-10       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.